Current Renal Cancer chemotherapy regimens are listed here.
https://www.cancertherapyadvisor.co...mens/renal-cell-carcinoma-treatment-regimens/
The combination of OPDIVIO and YERVOY seems to be the leading treatment. It looks like Sutent was the previous standard of care.
https://www.opdivo.com/advanced-ren...on/about-opdivo-yervoy/clinical-trial-results
So what's the opportunity for Bisantrene:
- OPDIVIO is a PD-1 inhibitor
- PD-1 inhibitors are susceptible to resistance
https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-020-00212-5- Inhibiting FTO can make PD-1 inhibitors work better (that's been shown for Melanoma)
https://www.nature.com/articles/s41467-019-10669-0- 90% of ccRCC are caused by mutations in the von Hippel-Lindau (VHL) tumour suppressor gene
https://www.researchgate.net/public...in_Sporadic_Conventional_Renal_Cell_Carcinoma- FTO was found to be synthetically lethal in cells with inactive VHL. Inhibition of FTO was found to kill VHL(-) ccRCC cancers.
https://pubmed.ncbi.nlm.nih.gov/32817424/
I can see a head to head battle between BMS and Merck and potentially a keen interest in what Bisantrene could do to make their PD-1 inhibitors work better.
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO
Pillar 1 - FTO, page-3
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.69 |
Change
0.010(0.60%) |
Mkt cap ! $287.1M |
Open | High | Low | Value | Volume |
$1.69 | $1.70 | $1.65 | $89.01K | 53.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2342 | $1.69 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.70 | 5 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2342 | 1.685 |
1 | 3664 | 1.680 |
1 | 5077 | 1.660 |
1 | 1265 | 1.650 |
1 | 612 | 1.635 |
Price($) | Vol. | No. |
---|---|---|
1.695 | 5 | 1 |
1.700 | 11000 | 1 |
1.730 | 2399 | 1 |
1.750 | 952 | 2 |
1.775 | 1328 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online